vTv Therapeutics (VTVT) announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes
- Buy Rating for vTv Therapeutics: Promising Potential of Cadisegliatin in Type 1 Diabetes Treatment
- vTv Therapeutics reports Q1 EPS (77c), consensus (81c)
- vTv Therapeutics reports reinitiation of screening in CATT1 Phase 3 trial
- VTVT Upcoming Earnings Report: What to Expect?